Nevertheless, the use of inhibitors of the BCR signaling pathway (e.g. BTK inhibitors) and thus the proliferation of CLL cells has significantly improved the therapeutic options and led to permanent remissions, even in high-risk and refractory CLL patients. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.